Indicator full name: Public pharmaceutical expenditure as % of total pharmaceutical expenditure
- Country/Area (COUNTRY/AREA)
- Supranational group of countries (COUNTRY_GRP)
- Sex (SEX)
- Year of measure (YEAR)
Years data is available: 1970—2020
Last updated: 01 September 2022
- North Macedonia
- WHO European Region
- Members of the European Union
- Members of the EU before May 2004 (EU15)
- Members of the EU after May 2004 (EU13)
- Nordic countries
- Small countries
The following abbreviations are used in the indicator titles:
Indicator code: E992709.T
The publicly financed share of total pharmaceutical expenditure. See 992708 above.
The OECD Health Database is used as the primary data source for those countries that are OECD Member States._
B&H, Health Insurance Fund of Federation of B&H; Health Insurance Fund of Republic of Srpska;
Department for Health of Brcko District
Pharmaceuticals consumed in hospitals are excluded.
Estonia has provided public pharmaceutical expenditure as % of total pharmaceutical expenditure data
for year 2009-2014.
Methodology. GDP estimates refer to ESA 2010 Methodology
Source: National Accounts, Central Bureau of Statistics.
Data for the period 1992-2012 have been estimated on the basis of the updated version of the
classification of economic activities (Ateco 2007, the national version of Nace Rev. 2) and of
products by activity (CPA 2008) and are consistent with the revised time series of national
methodology. Since 2013 methodology of SHA2011 is used.
Deviation from the definition: Since 2013 current expenditure on health care is used instead of
total health expenditure.
onwards: Health and social care accounts.
Note: The sudden increases and decreases in trend are due to changes in the financing system.
Deviation from the Definition: Data as at 31st December.